Ingersoll Rand Inc. (NYSE: IR) — The Margins Doubled, the Returns Didn’t: A Brilliant Operator Earning Its Cost of Capital

Independent equity research. Report date: 2026-06-26. Price reference: ~$81.37 (close 2026-06-26). All figures USD unless noted.

⚡ Claude’s Take

This block is the author’s own independent opinion and general information only — not investment advice. The analysis that follows takes no position and carries no price target; the single exception is this block.

Verdict: HOLD / fairly valued. Accumulate only on weakness in the high-$50s–high-$60s (~13–15x EV/EBITDA, ~18–20x adjusted earnings). Not a short. Conviction: medium.

Ingersoll Rand is one of the best-run industrial operators in America, and that is precisely the trap. Under Vicente Reynal the company has done something genuinely impressive — it took a sleepy compressor business and, through the IRX/“80-20” operating system plus a relentless bolt-on machine, drove operating margin from 6.9% (2020) to 19.7% (2025) and EBITDA margin from 17% to 26%. The aftermarket annuity is real, the balance sheet is a fortress (~1.5x net debt, ~$5B of M&A firepower), and free cash flow converts at ~95% of adjusted earnings. If you only read the margin chart and the adjusted-EPS bridge, this is a compounder you hold forever.

But the cash-on-cash truth is sobering and it is the whole bear case: full-capital ROIC has been stuck at ~6–8% for four straight years — at or below the cost of capital — even as margins doubled. The 21% headline ROE is an artifact of a balance sheet whose tangible common equity is negative (~–$2.6B); $12.7B of goodwill and intangibles sit on $18.3B of assets. The wonderful underlying businesses are being diluted to a WACC-level return because IR pays full prices for them. Worse, organic volume was negative in both 2024 and 2025 — the “compounder” isn’t organically compounding; it is buying revenue and capturing margin on a flat-to-shrinking volume base. The ILC Dover platform deal ($2.35B, 2024) was impaired ~$387M within ~18 months — direct evidence the machine misfires on bigger bets. Management is paid on Adjusted EPS and relative TSR with no return-on-capital hurdle anywhere in the proxy, which rewards exactly this goodwill-funded growth, and insiders have bought zero shares on the open market through a 23% de-rate while the CEO sold ~1.4M.

The reason this is a HOLD and not an AVOID is price. Unlike the parade of richest-ever industrials, IR has already de-rated — ~23% off its Nov-2024 ATH — to a middling 63rd-percentile multiple versus its own decade. The factor tape confirms it: momentum has been bled off (negative 12-month relative strength), but value buyers haven’t arrived because at ~17x EV/EBITDA it still embeds the flywheel-spins-forever premium. At ~$81 you are paying roughly half for a very good in-place business and half for the assumption that ~$1.3B/yr keeps getting redeployed accretively — a fair, not generous, bet. Framing: a quality-lite serial-acquirer that de-rated to fair, not to cheap. Tag: “the margins doubled, the returns didn’t.”

• Flips bullish if: organic volume re-accelerates above ~3% with incremental margins back above 40% AND deal-level ROIC visibly clears WACC (post-ILC-Dover discipline) — i.e., the flywheel is shown to create value, not just add EPS.
• Flips bearish if: organic stays ~1% or negative, another large platform deal is impaired, and the multiple converges toward de-rated Roper (~13–14x) → high-$50s.

📈 Stock Price Action — Five-Year Event Map

Factual price history, not a recommendation. Price moves are FACTS from the adjusted daily series; attributed causes are INTERPRETATION.

Ingersoll Rand (as the post-2020 Gardner Denver/Ingersoll-Rand Industrial combination) has run a full momentum cycle: from a ~$19 COVID low to a $105.19 all-time high (Nov-25-2024), then a give-back to ~$81 today — −22.6% off the ATH, with a 52-week range of $68.54 (May-19-2026) to $98.71 (Feb-17-2026) and a 5-year intraday low of $39.68 (Jul-2022). The stock sits in the middle of its own post-peak range — past the euphoria, not yet washed out.

Cycle narrative. (1–2) The 2020 RMT merger created the modern IR at the COVID bottom; the reflation trade plus the first visible IRX margin gains drove a triple off the low. (3) The 2022 rate shock de-rated the whole quality-compounder complex, IR included, to ~$41. (4) From there a clean two-and-a-half-year compound to a $105 ATH as margins kept expanding and the bolt-on cadence stayed high. (5–6) The peak broke in late 2024 as organic volume turned negative and tariffs entered the narrative; the Aug-2025 Q2 print was the one genuinely stock-specific shock. (7–9) Since then the stock has chopped in a $68–$99 band — a 29% rally, a 31% give-back, and a 19% bounce — a “show-me” range-trade rather than a trend, exactly what you’d expect of a de-rated compounder whose organic line hasn’t yet inflected.

1. Executive Summary

Ingersoll Rand is a $7.65B-revenue (FY2025) global manufacturer of mission-critical air and gas compression, vacuum, blower, and precision fluid-management equipment, operating through two segments — Industrial Technologies & Services (ITS, ~79% of revenue) and Precision & Science Technologies (P&ST, ~21%). It is the post-2020 combination of Gardner Denver (KKR’s 2017 IPO) and the Industrial segment spun out of the old Ingersoll-Rand plc, run by CEO Vicente Reynal on a Danaher-style decentralized operating system branded IRX layered with an 80/20 economic-value-add discipline.

The bull case in one line: a self-improving niche-industrial compounder with a genuine aftermarket annuity, fortress balance sheet, and a proven M&A flywheel that has doubled operating margins since 2020 — a younger Roper/Ametek.

The bear case in one line: consolidated returns on capital sit at the cost of capital (~8% ROIC), organic volume is shrinking, and the growth is bought rather than earned — a margin-engineering and acquisition story dressed in compounder clothing.

The evidence sides more with the skeptic than the multiple does. Margins are real and impressive (gross 43.6%, adjusted EBITDA 27.4%, op 19.7%), free cash flow is high-quality (~$1.22B FY2025, ~90% conversion, 1.8% capex intensity), and the balance sheet carries ~$5B of acquisition firepower at ~1.5x leverage. But ROIC has been flat at 5.7%/7.7%/8.1%/7.7% across 2022–2025 despite the margin doubling, because each deal adds goodwill that earns only a WACC-level return; tangible common equity is negative ~$2.6B. Organic volume fell ~3.3% in 2024 and ~1.3% in 2025; reported 2024 “organic growth” was entirely price. The $2.35B ILC Dover platform acquisition (2024) was impaired ~$387M within ~18 months. Management’s incentive plan contains no return-on-capital metric — it pays for Adjusted EPS and relative TSR, which structurally rewards goodwill-funded M&A. Insiders have made zero open-market purchases through the de-rate.

On valuation, IR is the rare member of its cohort that is not at a richest-ever multiple: it trades at ~17.5x EV/EBITDA and ~23x adjusted earnings — a 63rd-percentile composite versus its own decade, having already fallen ~23% from its Nov-2024 peak. That is fair, not cheap. Roughly half the equity value rests on the in-place business and half on the perpetuity of the acquisition machine; with ROIC ≈ WACC and a recent large-deal misfire, that second half deserves scrutiny. The body that follows takes no position; the labeled Claude’s Take above does.

2. Business Overview

Ingersoll Rand designs, manufactures, sells, and — critically — services flow-creation and industrial equipment, organized into two reporting segments.

Industrial Technologies & Services (ITS) — $6,056.4M revenue FY2025 (79% of total), 28.9% adjusted segment EBITDA margin. This is the historic core: air and gas compressors (rotary screw, centrifugal, reciprocating, oil-free), vacuum pumps and systems, blowers, plus fluid handling/transfer, power tools, and material-lifting equipment. Brands include Ingersoll Rand, Gardner Denver, CompAir, Nash, Elmo Rietschle, Robuschi, and others. The economic heart of ITS is the aftermarket — replacement parts, consumables (air filters, lubricants), service contracts, controls, and air-treatment — which is 40.6% of ITS revenue and rises over the 10–12-year life of an installed compressor. Management’s own framing: “the aftermarket revenue generated by a compressor over the product’s life cycle will typically exceed its original sale price” (FY2025 10-K).

Precision & Science Technologies (P&ST) — $1,594.5M revenue FY2025 (21% of total), 30.0% adjusted segment EBITDA margin. Higher-margin, lower-cyclicality specialty businesses split into two sub-units: Precision Technologies (positive-displacement and metering pumps — Milton Roy, Dosatron, Seepex, Albin — for dosing, sampling, and precise fluid transfer in water treatment, chemical, and agricultural markets) and Life Science Technologies (sterile/single-use fluid management, diaphragm/peristaltic pumps, gas analysis, and — via the 2024 ILC Dover acquisition — biopharma single-use systems and, incongruously, aerospace/defense engineered films and space suits). P&ST aftermarket is lower (20.6%) but its end markets (life sciences, water, medical) are more secular and less PMI-sensitive.

How it makes money. IR sells equipment through a hybrid of direct sales and independent distributors, then earns a recurring, higher-margin annuity servicing the installed base. The model resembles a razor/razor-blade business for the ITS third of revenue and a niche-specialty-pump business for P&ST. Roughly 36.5% of consolidated revenue is recurring aftermarket; the balance is competitively-bid original equipment tied to industrial capex.

Scale and footprint. ~21,000 employees, headquartered in Davidson, North Carolina; sales across North America, EMEIA, and Asia-Pacific, with ~40+ brands. The company has made ~16 acquisitions in 2025 alone and >50 since 2021 — M&A is not a sideline; it is the operating model.

Verdict: A diversified portfolio of decent-to-good niche industrial franchises bound together by a strong operating system and a recurring-aftermarket overlay. The business is well-run and cash-generative; whether it is a moat is the subject of the relevant section–the relevant section.

3. Industry Dynamics

Market structure. The air-compressor and flow-control market is, in IR’s own words in its 10-K, “highly fragmented.” The global industrial air-compressor TAM is roughly $6B, growing low-single-digits (~3%), with vacuum, blower, and flow-control adjacencies adding several billion more. The top of the market is consolidated — Atlas Copco is the global #1 at ~25% share, with Ingersoll Rand the clear #2 — but a long fragmented tail (Kaeser, Sullair/Hitachi, Elgi, Kaishan, Atlas’s own multi-brand stable, plus thousands of regional players) prevents oligopoly pricing. In precision pumps and flow-control, the competitive set is IDEX, Dover (PSG), Graco, Roper (Neptune/Cornell), Watson-Marlow (Spectris), SPX Flow, and Xylem-adjacent players — again fragmented and niche-by-niche.

Demand drivers and cyclicality. ITS demand tracks industrial production, manufacturing PMI, and capacity utilization — compressed air is the “fourth utility” of a factory, so original-equipment orders are pro-cyclical while the aftermarket is counter-cyclical-ish (factories service rather than replace in downturns). End-market exposure spans general industrial, oil & gas/petrochemical, food & beverage, life sciences, and increasingly data centers (compressed air and gas for cooling/manufacturing) and semiconductors. P&ST skews more secular (water treatment, biopharma, agriculture). The aftermarket richness (36.5% of revenue) genuinely dampens the cycle — but it does not eliminate it, as the negative organic volume of 2024–2025 (a soft industrial-capex environment) demonstrates.

Barriers to entry and profit pools. Barriers are moderate and local, not structural. They derive from (a) installed-base service density and OEM-fit parts (customer captivity), (b) distributor and service-branch coverage, © engineering/application know-how in niches, and (d) brand reputation for uptime in mission-critical settings. These barriers are real enough to support mid-20s%-and-up segment margins for the well-run leaders (Atlas Copco’s Compressor Technique runs ~24% operating margin; IR’s ITS ~29% segment EBITDA), but they are not a protected oligopoly that earns supernormal returns on capital — the fragmented tail and the capex-cyclicality keep it honest.

Capital cycle (Marathon lens). The industry is mature and capital-disciplined at the top; the leaders have rationalized and consolidated (IR and Atlas both via serial M&A), which is supply-side favorable. But the high posted returns of the leaders are attracting capital into the M&A market itself — bolt-on multiples for niche flow-control assets have risen, which is exactly why IR’s consolidated ROIC sits at WACC: the value is being competed away in the acquisition price, not in the operating market. This is the subtle capital-cycle risk specific to serial acquirers.

Verdict: a structurally GOOD-not-GREAT industry. Consolidated at the top, aftermarket-rich, secularly growing low-single-digits, and cyclically exposed to industrial capex. It supports high margins for skilled operators but is fragmented and competitive enough that it does not, on its own, confer a durable high-return moat. The returns IR earns above the industry come from execution and M&A, not from owning a structurally advantaged position.

4. Competitive Position

Name the moat. In Greenwald’s taxonomy, IR’s advantage is primarily customer captivity (switching/search costs on the installed base, OEM-fit parts, mission-critical uptime, service-relationship lock-in) reinforced by distribution density and niche leadership (the 10-K describes IR as a market leader in positive-displacement pumps and a top-two player in compression). It is explicitly not an economies-of-scale moat at the corporate level — IR is roughly 2.5x smaller than Atlas Copco in compression, so it is the challenger, not the scale leader.

The aftermarket annuity — the one genuine moat element. This is the strongest part of the thesis and it is real. ITS aftermarket revenue is 40.6% of segment sales (≈ Atlas Copco’s Compressor Technique aftermarket at ~41%), it carries higher margins than equipment, and it recurs over a decade-plus installed-base life. Management is layering a connected/digital service offering on top, targeting a ~$1.0B recurring-revenue run-rate by end-2027 (>$450M in 2024, with a ~$1.1B backlog). If this annuity disappeared, ITS margins and stability would deteriorably fall — so by the test (“would a financial outcome deteriorate without it?”), the aftermarket passes as a moat. The problem is that it covers only ~⅓ of the business; the other ~⅔ is competitively-bid original equipment with no recurring lock.

The operating system — execution, not moat. The single most striking fact about IR is that operating margin doubled from 6.9% (2020) to 19.7% (2025) and EBITDA margin went 17%→26%. That magnitude of self-improvement is the signature of an operating system (IRX + 80/20/EVA), not a widening structural moat. It is the same DNA as Ametek, Roper, and Danaher: take decent niche businesses, apply a disciplined toolkit, and capture latent margin. This is a genuine and valuable capability — but it is a management advantage that travels with the team and the playbook, not a structural advantage embedded in the assets. The market-share-stability test is ambiguous: IR holds firm regional positions (#1 in North American compression at ~28%) but is gaining/losing share niche-by-niche through M&A rather than holding a stable fortress.

The ROIC test — fails at the corporate level. Greenwald’s clinching test for a moat is sustained high returns on capital. IR’s full-capital ROIC is ~7.7% (FY2025) and has been pinned in the 5.7%–8.1% band for four years — at or below an estimated 9–10% WACC, and far below Greenwald’s 15–25% moat threshold. The underlying businesses earn high returns (which is why segment margins are ~29–30%), but IR converts them to only cost-of-capital returns at the consolidated level by paying full prices and stacking goodwill. This is the identical artifact seen in Ametek (consolidated GAAP ROIC ~12% vs ~29% underlying) and Roper (~6%) — but IR sits at the low end of that cohort.

Versus Atlas Copco specifically. Atlas is the benchmark: global #1, ~25% compression share (~2.5x IR), Compressor Technique operating margin ~24%, aftermarket ~41%, and — decisively — a higher and more stable return on capital with a lower goodwill burden (Atlas grew more organically). IR has closed the historical margin/aftermarket-mix gap to Atlas via IRX — a real achievement — but remains the smaller, more-acquisitive, lower-ROIC #2. IR competes on regional leadership (North America) and niche depth, not on global scale superiority.

Verdict: a real but NARROW and per-business moat — not a structural franchise. The aftermarket annuity is genuine and defends ~⅓ of revenue. The rest of IR’s superior profitability is execution (IRX) plus M&A, neither of which is a durable structural moat that shows up as high returns on capital. IR is the lowest-structural-moat member of the decentralized-acquirer cohort (AME/ROP), and it is the corporate ROIC — not the segment margin — that tells the truth.

5. Growth History and Forward Opportunities

Headline growth looks strong; its composition is the problem. Revenue nearly doubled from $3.97B (2020) to $7.65B (2025): 2021 $5.15B, 2022 $5.92B, 2023 $6.88B, 2024 $7.24B, 2025 $7.65B — a ~14% CAGR. But decomposing the recent years exposes the engine:

• FY2024 revenue +5.2%: acquisitions +$471M, price +$153M, organic volume −$242M (−3.3%), FX −$24M. Reported “organic growth” was entirely price — volume shrank.
• FY2025 revenue +5.7%: acquisitions +$420M, FX +$92M, organic −$96M (−1.3%).
• FY2026 guide: ~1% organic + ~2% M&A growth at the midpoint.

So for two consecutive years organic volume has been negative, and the FY2026 guide leans on M&A for the majority of growth. Total revenue is rising, but per-share earnings tell the real story: Adjusted Net Income was essentially flat at ~$1,348–1,349M in 2024 and 2025 despite ~11% two-year revenue growth and billions in M&A. Adjusted EPS rises mainly because the share count shrinks via buybacks, not because the business is compounding organically. This is the defining tension: the “compounder” is currently buying revenue and capturing margin on a flat-to-shrinking volume base.

Segment growth quality (Q1-2026). ITS organic revenue −1.6% (the cyclical core, soft); P&ST organic +4.4%, led by Life Science Technologies posting double-digit order growth. P&ST — and within it the secular Life Science and Precision Technologies units — is the genuine organic bright spot; ITS is in a volume trough awaiting an industrial-capex recovery. Q1-2026 book-to-bill was ~1.0 (orders up 5% reported but organic orders −3%, roughly flat ex one large long-cycle project), with management framing short-cycle order trends as improving into the back half.

Forward opportunities (real, but mostly M&A- and theme-leveraged).

• The M&A flywheel — ~$5B of firepower aimed at sub-$200M bolt-ons in compression, vacuum, pumps, and flow-control. This is the primary growth driver and the primary risk (the relevant section).
• Recurring/connected revenue — the ~$1.0B-by-2027 digital-service target adds higher-margin, stickier revenue on the installed base.
• Secular end-markets — data centers, life sciences/biopharma single-use, water treatment, and sustainability-driven oil-free/energy-efficient compressor upgrades. These are credible but indirect — IR is a component/equipment supplier into these themes, not a pure-play.
• Cyclical recovery — an industrial-capex/PMI upturn would flip ITS organic volume positive and prove out the 40%+ incremental-margin story currently unprovable on negative volume.

Verdict: LOW-quality top-line growth at present. The growth is real in dollars but bought, not earned — price + M&A + margin capture over a negative organic volume base, with flat adjusted net income. It becomes high-quality only if organic volume re-accelerates (a cyclical bet) or if the M&A continues at genuinely value-creating returns (which the ROIC math currently disputes).

6. Capital Allocation

This is the decisive workstream for IR, because the entire thesis hinges on whether the M&A machine compounds value or merely compounds revenue.

The M&A scorecard. IR deployed ~$5.67B on acquisitions across 2021–2025 (2021 ~$975M; 2022 $247M; 2023 $963M; 2024 $2,959M; 2025 $525M across ~16 deals). The model is genuinely two-tiered:

• A high-volume funnel of sub-$200M bolt-ons (Transvac, Termomeccanica/Adicomp ~€160M, SSI, G&D Chillers, Cullum & Brown, Del Pumps, etc.) tucked into the core compression/flow franchises and run through IRX — plausibly accretive and the right use of the platform.
• One large platform bet outside the core — ILC Dover ($2,349.7M + up to $75M earnout, June 2024) — biopharma single-use and aerospace/defense (space suits). This deal destroyed value almost immediately: in Q2-2025 IR booked $170.3M (Biopharma) + $59.4M (Aerospace & Defense) goodwill impairments + $36.1M tradename + a separate $120.9M equity-method investment writedown to zero — ~$387M of ILC-Dover-linked destruction in one quarter, ~16% of the purchase price, within ~12 months of closing. The A&D writedown cited “a reduction in business with a significant customer.” The residual Life Sciences unit carries only a ~30% impairment cushion versus ≥85% elsewhere — more risk pending.

The ROIC verdict — empire-shaped outputs from disciplined-looking inputs. On process, the flywheel looks like Danaher: a disciplined ex-Danaher CEO, the IRX toolkit, and fortress dry powder. On outputs, the consolidated math is empire-building-shaped: ROIC has been flat at ~5.7%→7.7%→8.1%→7.7% (2022–2025), parked at or below WACC for years, and the 21% headline ROE is a financial-engineering artifact of negative ~$2.6B tangible common equity (goodwill + intangibles = ~70% of assets). Each deal adds goodwill that earns a WACC-level return; the great segment economics are diluted to the cost of capital. The bull’s rebuttal — that incremental bolt-ons earn high returns and the average is dragged by legacy/large deals — is plausible but unproven by the disclosure, and the one large deal we can observe (ILC Dover) failed.

Buybacks, dividend, timing. 2025 was a $1,018M buyback year — ~4x the steady ~$260M of 2022–2024 — executed at/near all-time highs (~$86 average), which is pro-cyclical (buying most when the stock was richest). It shrank the count ~2.9% (402.9M→391.1M). The dividend is a token ~$32M (~$0.08/share, ~5% payout), flat for years — IR is explicitly not a dividend story. Capital priority is M&A first, opportunistic buybacks second, dividend a rounding error.

Insider behavior — a soft negative. Across 164 Form 4s (Jan-2024→May-2026), there were ZERO open-market purchases (code P) by anyone, at any price. Insiders sold ~1.67M shares net; CEO Reynal alone sold ~1.40M shares (mostly 10b5-1 exercise-and-sell at $83–$100) and holds ~1.26M shares (~$100M, <1% of the company). Planned selling is not itself damning, but the complete absence of conviction buying through a 23% de-rate is notable. KKR fully exited in 2021 — no sponsor overhang.

Compensation — the structural flaw. Directly damning for a serial acquirer: “ROIC”/“return on capital” appears zero times in the 2026 proxy. The annual MIP is Adjusted EPS + Free Cash Flow; LTI PSUs (50%) are Relative TSR vs. S&P 500 Industrials; the CEO’s 1.0M-PSU 2022–26 mega-grant is Adjusted EPS CAGR + a TSR target. No capital-efficiency hurdle exists anywhere — management is paid to grow EPS and beat TSR, which rewards goodwill-funded M&A even when it earns ~WACC. This is the single most important governance fact in the file: the incentive system is structurally biased toward exactly the behavior the ROIC numbers flag. (The genuine offsetting positive is the Ownership Works all-employee equity culture — 28,000+ employees granted since 2017, grant value scaled from $300M toward ~$1B — a real cultural asset.) Reynal’s 2025 SCT comp was $16.2M.

Balance sheet. Total debt $4,784.7M (all senior unsecured, post-2024 refinancing; no secured/term debt), cash $1,248.8M → net debt ~$3.54B (~1.5–1.7x EBITDA), ~5.0% weighted-average rate, back-loaded maturities (bulk 2033/34/54). ~$5.2B undrawn capacity ($2.6B revolver + $2.6B CP); covenant ≤3.5x (step to 4.0x post-acquisition). Room for $3–4B+ more M&A.

Verdict: a superb operator running an acquisition machine whose consolidated returns sit at the cost of capital, incentivized on EPS/TSR rather than capital efficiency, with the next large platform deal carrying real ILC-Dover-style risk. The bolt-on machine is credible; the big diversifying deal failed; the comp plan rewards the spending regardless. Capital allocation is the thesis’s weakest link, not its strength.

7. Changes and Headwinds — Last Two Years

Strategic / portfolio. The dominant event is the 2024 ILC Dover acquisition (~$2.35B) — IR’s largest-ever deal and its push into biopharma single-use and aerospace/defense — followed by its ~$387M impairment in Q2-2025, a fast and visible capital-allocation black eye. Alongside it, a steady cadence of bolt-ons continued (Termomeccanica/Adicomp ~€160M and G&D Chillers in 2025; multiple smaller deals), and the $1B 2025 buyback marked a step-up in shareholder returns at high prices.

Operating environment. A soft industrial-capex backdrop drove organic volume negative in 2024 and 2025; orders have been choppy (Q1-2026 organic orders −3%, ~flat ex one project; book-to-bill ~1.0). Tariffs — specifically the recent Section 232 changes — are an active 2026 headwind, dilutive to ITS margins (ITS adj-EBITDA margin −210bps YoY in Q1-2026), with management explicitly building tariff/inflation impacts into FY2026 guidance and counting on price/cost recovery and restructuring to offset in the back half.

Guidance. FY2026 guide: revenue ~1% organic + ~2% M&A; Adjusted EBITDA $2.13–$2.19B; Adjusted EPS $3.45–$3.57 (~5% at midpoint); ~95% FCF/adj-NI conversion; ~394M shares. The guide embeds a back-half-weighted recovery and tariff mitigation — both partly outside management’s control.

Leadership/board. CEO Vicente Reynal (Chairman & CEO) and CFO Vik Kini remain in place — stable, founder-operator-style leadership with no succession question near-term. KKR’s full 2021 exit removed the sponsor overhang.

Verdict: net thesis-WEAKENING over the period. The two years brought margin progress (positive) but also negative organic volume (negative), a large impaired acquisition (negative), a pro-cyclical buyback (mixed), and a fresh tariff headwind (negative). The operating system kept delivering on margin while the growth engine sputtered and the capital-allocation discipline took a visible hit.

8. Risk Analysis (Risk Matrix)

Catastrophic-loss assessment: very low. IR is investment-grade, modestly levered (~1.5x), asset-light, and diversified across thousands of customers and dozens of niches. The realistic downside is a de-rating and value-neutral compounding outcome, not impairment of the enterprise.

9. Risk Analysis Narrative — The Two That Matter

Two risks dominate and both point at the same place: the gap between operating excellence and capital returns.

First, value-neutral compounding. If ROIC stays at WACC, the M&A flywheel adds revenue and (via buybacks) adjusted EPS, but creates little intrinsic value per dollar deployed — the company runs hard to stand still on a per-share economic basis. Four years of flat ROIC through a doubling of margins is strong evidence this is the base rate, not a transient. The incentive plan, by rewarding EPS/TSR with no capital hurdle, actively encourages more of it.

Second, the next big bet. ILC Dover demonstrated that when IR steps outside its core into a larger, less-familiar platform, it can overpay and impair quickly. With ~$5B of firepower and a comp plan that rewards EPS growth, the structural temptation to do another large, multiple-elevating deal is high — and that is precisely where the risk of value destruction concentrates. A disciplined “bolt-ons only” posture would be reassuring; the disclosure and incentives don’t guarantee it.

10. Valuation Discussion (Embedded Expectations)

Where the multiple sits. At ~$81.37, IR’s market cap is ~$31.8B and EV ~$35.4B. On TTM figures that is ~17.5x EV/EBITDA, ~4.6x EV/Sales, and on adjusted earnings (~$3.36 FY2025 adj EPS; $3.45–$3.57 FY2026 guide) ~23–24x adjusted P/E (the GAAP P/E of ~54x is noise — it is depressed by ~$377M/yr of acquired-intangible amortization and the 2025 impairment). Crucially, on its own decade, IR’s AZI composite valuation percentile is 63rd (P/E 75.8th, P/B 55.3rd, P/S 59.0th) — middling, having de-rated ~23% from its Nov-2024 peak. This is the rare quality-industrial that is not at a richest-ever multiple.

Cohort comparison. Against the decentralized-acquirer peer set: Ametek ~22.6x EV/EBITDA (94th own-history percentile — rich), Roper ~14x / 15–16x forward (de-rated hard, ~2nd percentile), with Dover, IDEX, and Graco generally in the mid-teens-to-low-20s. IR’s ~17.5x sits below AME and above de-rated ROP — a defensible mid-cohort placement given IR earns lower ROIC (~8%) than AME (consolidated ~12%, underlying ~29%) but offers a similar margin profile and a comparable flywheel narrative. Atlas Copco, the higher-ROIC scale leader, typically commands a premium to IR — appropriately.

Embedded-expectations read. At ~17.5x EV/EBITDA for a business guiding ~1% organic + ~2% M&A growth with ~8% ROIC, the market is capitalizing continuation of the IRX flywheel as a perpetuity. A reverse-DCF/SOTP read: the in-place business (~1% organic, flat margins) on its own supports only ~13–15x EV/EBITDA; the ~2.5–4.5 turns of premium above that is the assumed perpetual redeployment of ~$1.3–1.4B/yr of FCF into ~10–12x bolt-ons that re-rate to ~17x inside IR. Roughly half the equity value is the in-place business and half is the assumed-permanent acquisition machine. The risk the market may under-price is that with ROIC ≈ WACC, each deal creates far less value than the AME/Danaher comparison implies, and ILC Dover is recent evidence the machine misfires on larger bets.

Scenario analysis (3-year, directional; no point target).

Synthesis. The base case roughly is the current price — IR is approximately fairly valued at ~$81, de-rated to middling rather than to cheap. The asymmetry is not compelling at today’s level: the bull requires a cyclical organic inflection and a re-rating toward AME, while the bear requires only that the status quo (soft organic, WACC-level ROIC) persists and the multiple converges toward de-rated Roper. No price target and no recommendation in this section — the directional read for Claude’s Take is fair-value ~$70–85, accumulate-attractive only high-$50s–high-$60s.

11. Variant Perception

Consensus. The Street treats IR as “the next Roper/Ametek of compression and flow-control” — a self-improving compounder whose IRX flywheel keeps delivering double-digit adjusted-EPS growth, where the 2025–2026 de-rate is a buyable pause in a long compound. Sell-side price targets cluster above the current price; the bull narrative is margin durability + M&A optionality.

The strongest bull case. P&ST/Life Science momentum and a short-cycle order inflection re-accelerate organic growth to mid-single-digits; the 40%+ incremental-margin engine re-engages on positive volume; disciplined bolt-ons (learning from ILC Dover) compound accretively; margins push to 28–29%; and the multiple re-rates toward AME (~22x). That path supports $120+. The balance sheet (~$5B firepower, 1.5x leverage) and the genuine aftermarket annuity make this credible, not fanciful.

The strongest bear case. Organic growth is structurally ~1% (mature, fragmented, cyclical end-markets), ROIC stays ≈ WACC so the flywheel adds EPS but little intrinsic value, ILC Dover proves large deals misfire and another one looms, tariffs persist, and the multiple converges toward de-rated Roper (~13–14x) → high-$50s. The four-year flat-ROIC record, two years of negative organic volume, flat adjusted net income, and a comp plan with no capital hurdle all support this as the base rate, not the tail.

The 3–5 swing assumptions.

1. Organic inflection: does volume re-accelerate above ~3%, or stay stuck ~1%? (Cyclical + secular.)
2. Incremental deal ROIC: do incremental bolt-ons demonstrably clear WACC, or is ~8% the true marginal return? (Disclosure gap.)
3. Tariff/Section-232 drag: transitory and price-recoverable, or a structural margin tax?
4. Multiple regime: does IR command an AME-like ~22x or a de-rated-ROP ~14x? (The single biggest valuation lever.)
5. Capital-allocation discipline post-ILC-Dover: bolt-ons only, or another large platform bet?

Factor-positioning input. The tape corroborates a “show-me” read: IR loads on none of Momentum, Value, or Growth (all L1-zeroed in the FactorsToday model) — it is positioned as a Quality-lite, dividend/credit-sensitive industrial mid-cycle, with negative 12-month relative strength (rs_12m −2.2, rs_peak −22.6) and a negative trailing-year Sharpe. The de-rate has been orderly and beta-driven (only one large idiosyncratic down-day, the Aug-2025 Q2 print) — not a falling knife, but also not yet a value setup. The crowd has left the momentum trade; value buyers haven’t arrived because IR isn’t cheap. That favors patience over chasing — exactly the posture Claude’s Take adopts.

Where consensus is most likely offsides: in conflating operational excellence (real, proven) with capital-returns excellence (absent — ROIC at WACC). The market pays an AME-adjacent multiple for a business whose consolidated cash-on-cash returns are materially lower. If that gap is recognized, the multiple compresses; if organic inflects and deals prove accretive, it is vindicated.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the incremental (marginal) ROIC on recent bolt-ons? The consolidated ~8% is dragged by legacy + large deals; IR does not disclose deal-level returns. The single most important missing datum.
2. What is the true normalized organic growth rate through a full cycle, stripped of price and M&A — 1%, 3%, or negative?
3. Will there be another large platform deal, and is there any internal capital-return discipline (a hurdle rate) governing it, given the proxy shows none?
4. What is the residual ILC Dover Life Sciences impairment risk given the disclosed ~30% cushion vs ≥85% elsewhere?
5. How much of the 2026 tariff drag is structurally recoverable via price vs. a permanent margin tax?
6. Will the $1.0B-by-2027 recurring-revenue target materially raise the aftermarket mix and de-cyclicalize the model, or is it incremental?

14. What Must Be True

For the bull case (≥ mid-single-digit per-share value compounding from here):

• Organic volume must inflect positive (≥3%) on an industrial-capex/PMI recovery AND incremental margins must re-engage above 40%.
• Incremental M&A must demonstrably earn above WACC — i.e., consolidated ROIC must start rising, not stay pinned at ~8%.
• The multiple must at least hold ~17x (and ideally re-rate toward AME) — requiring the market to keep crediting the flywheel.
• Falsification test: if, over the next 4–6 quarters, organic volume stays ≤1% and consolidated ROIC fails to rise above ~9%, the bull thesis is broken — the compounder is confirmed value-neutral.

For the bear case (de-rate toward de-rated-acquirer multiples / value-neutral outcome):

• Organic growth must stay structurally ~1% or negative, confirming a mature/cyclical core.
• ROIC must remain ≈ WACC, with the M&A flywheel adding EPS but not intrinsic value; ideally another large deal stumbles.
• The multiple must converge toward ROP-de-rated ~13–14x.
• Falsification test: if organic volume re-accelerates above ~3% and ROIC climbs through ~10% over the next year, the bear thesis is broken — IR is genuinely compounding, and the current multiple is justified or cheap.

The elegance of IR is that both falsification tests key on the same two numbers — organic volume and consolidated ROIC. Watch those two lines; they will settle the debate.

15. Source Appendix

See the separate Source Appendix (Appendix B in the combined report) for the full citation list. Primary sources: Ingersoll Rand FY2021–FY2025 Forms 10-K (CIK 0001699150; iri-/gdi- filings, SEC EDGAR); Q1-2026 Form 10-Q (filed 2026-04-29); Q1-2026 earnings call transcript (2026-04-29) and FY2026 guidance 8-K; 2026 DEF 14A proxy; Form 4 corpus (2024–2026); ROIC.ai aggregated fundamentals and enterprise value (reconciled to filings); AZI price history and valuation-percentile index; third-party factor-model data; and public peer-company financials (AME, ROP, EMR, PH, GTLS, Atlas Copco) for cohort cross-read. All non-obvious facts are cited to source and date; management commentary is treated as hypothesis and validated against filings and external data.

APPENDIX A — Standard Diligence Questionnaire — Ingersoll Rand Inc. (NYSE: IR)

Report date 2026-06-26. Supplemental to the memo. Fact / Interpretation / Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company? The central debate is whether IR is “the next Roper/Ametek” (a genuine value-compounder) or a margin-engineering-plus-M&A story whose consolidated returns sit at the cost of capital. Sharp investors press on: (a) the gap between ~29–30% segment EBITDA margins and ~8% consolidated ROIC; (b) whether organic growth is structurally low (volume was negative in 2024 and 2025); © deal-level returns on bolt-ons (undisclosed); (d) the ILC Dover impairment as a discipline signal; and (e) the absence of any ROIC hurdle in compensation. (Interpretation.)

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Mixed. Margins are near cyclical highs (IRX-driven, structural), but organic volume is near a cyclical low (−3.3% 2024, −1.3% 2025; ITS in volume decline). Adjusted EPS is roughly flat (2024–25). So margins are elevated while volumes are depressed — net, earnings are mid-cycle with downside protection from the aftermarket and upside optionality from a volume recovery. (Fact + Interpretation.)

Driven by the external environment or internal actions? Both. The margin expansion (7%→20% op margin since 2020) is internal (IRX/80-20). The negative organic volume is external (soft industrial capex/PMI). (Interpretation.)

How stable are revenues? Moderately. ~36.5% recurring aftermarket dampens the cycle, but ~63% is original-equipment tied to industrial capex. Beta ~1.23. (Fact.)

Outlook for products/services? Secularly growing low-single-digits (compressed air is the “fourth utility”), with theme leverage to data centers, life sciences, water, and energy-efficient/oil-free upgrades. (Interpretation.)

How big is the market — growing, shrinking, domestic or international? Global, ~$6B air-compressor TAM plus multi-billion vacuum/blower/flow-control adjacencies, growing ~3%; ~⅔ of IR revenue is outside the US. (Fact + Assumption on exact sizing.)

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Stable-to-consolidating at the top (IR/Atlas Copco via M&A) but persistently fragmented in the tail. Not becoming a protected oligopoly. (Interpretation.)

How profitable is the business (ROIC, ROE)? ROE ~21% (FY2025) but that is a financial-engineering artifact of negative tangible common equity (~–$2.6B). Full-capital ROIC ~7.7% — at/below WACC. Segment EBITDA margins ~29–30%. The consolidated ROIC is the truth-teller. (Fact.)

How profitable is the industry — competitors, barriers? Skilled leaders earn mid-20s%+ operating margins; barriers are moderate (installed-base service density, OEM-fit parts, distribution, niche know-how) — real but local, not structural. (Interpretation.)

Can the business be easily understood? Yes — it makes and services compressors and pumps. The complexity is the M&A accounting, not the operations. (Fact.)

Can it be undermined by foreign low-cost labor? Partially in commoditized equipment (Asian compressor makers), but the aftermarket, service density, and mission-critical-uptime requirements insulate the high-margin third. (Interpretation.)

Do brands matter? Moderately — Ingersoll Rand, Gardner Denver, CompAir, Nash, Milton Roy carry installed-base trust and OEM-fit lock-in, but customers buy on uptime/reliability/total-cost more than badge. (Interpretation.)

Nature of competition? Regional and niche-by-niche vs. Atlas Copco (global #1, ~2.5x scale), Kaeser, Sullair, IDEX, Dover, Graco, Roper. IR competes on North American leadership and aftermarket depth. (Fact.)

Customers’ switching costs? Real on the installed base (OEM parts, service relationships, validated processes in life sciences) for ~⅓ of revenue; low on new original-equipment bids. (Interpretation.)

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The aftermarket installed base and the IRX operating capability are valuable but unbooked. Conversely, the booked $12.7B of goodwill/intangibles overstates economic capital quality (negative TCE). (Interpretation.)

Off-balance-sheet liabilities? Nothing unusual flagged — standard operating leases, pensions (~$134M), and the ILC Dover earnout (up to $75M). (Fact.)

How conservative is the accounting? Adjusted metrics add back ~$377M/yr of acquired-intangible amortization — a recurring structural cost of the roll-up, not a one-off, so “adjusted” earnings flatter true economics and ROIC. The 2025 impairment was, to management’s credit, taken promptly. (Interpretation.)

How CapEx-hungry? Not — capex ~1.8% of revenue; asset-light; FCF converts ~90–95% of adjusted NI. (Fact.)

Capital Allocation & Management

How much FCF, and how is it used? ~$1.22B FCF (FY2025). Priority: M&A first (~$5.67B over 2021–2025), opportunistic buybacks second ($1.0B in 2025 at ~$86, pro-cyclical), token dividend third (~$32M, ~$0.08/sh). (Fact.)

Significant acquisitions recently? Yes — ILC Dover ($2.35B, 2024, since impaired ~$387M) plus ~16 bolt-ons in 2025 (Termomeccanica/Adicomp, G&D Chillers, etc.). (Fact.)

Buying back shares? Yes, $1.0B in 2025 (count 402.9M→391.1M), but at near-record prices. (Fact.)

Issuing shares to insiders? SBC modest (~$53M); a notable all-employee equity culture (Ownership Works, 28,000+ employees). (Fact.)

Compensation policy? MIP = Adjusted EPS + FCF; LTI PSUs = relative TSR (50%) + Adj-EPS CAGR. No ROIC/return-on-capital hurdle — the key governance flaw for a serial acquirer. CEO 2025 SCT comp $16.2M. (Fact + Interpretation.)

Motivations of management? EPS growth and TSR outperformance — which structurally rewards goodwill-funded M&A regardless of cash-on-cash returns. Genuine operator pride/culture is also evident (IRX, ownership ethos). (Interpretation.)

Valuation & Market Data

ADR / MLP / K-1? No — ordinary US C-corp common stock, NYSE-listed. (Fact.)

Dividend policy? Token (~$0.08/sh, ~0.1% yield, ~5% payout) — not a dividend story. (Fact.)

How profitable (returns)? Margins excellent; consolidated ROIC ~8% (≈WACC) — the recurring caveat. (Fact.)

Net income diverging from cash flow? GAAP NI ($581M) is depressed vs. cash (FCF ~$1.22B) by ~$377M amortization + the 2025 impairment — cash generation materially exceeds GAAP earnings, which is favorable for cash quality but reflects the roll-up’s accounting drag. (Fact.)

Risks & Downside

What would cause the stock to decline? Multiple convergence toward de-rated-acquirer peers (~13–14x), persistent negative organic volume, another impaired large deal, or a sharper industrial downturn. (Interpretation.)

Risk of catastrophic loss? Very low — investment-grade, ~1.5x leverage, asset-light, diversified. (Interpretation.)

Chance of total loss? Negligible. The realistic bear is a de-rate and value-neutral compounding, not impairment of the enterprise. (Interpretation.)

Recent News & Events

Has the business environment changed recently? Yes — soft industrial capex (negative organic volume 2024–2025), a fresh Section-232 tariff headwind in 2026, and the ILC Dover impairment. (Fact.)

Significant acquisitions / accounting changes / new markets? ILC Dover pushed IR into biopharma single-use and aerospace/defense (the impaired bet); ongoing bolt-on cadence; ~$1.0B-by-2027 recurring-revenue initiative. No major accounting-policy change. (Fact.)

Management/board changes? Stable — Reynal (Chairman & CEO), Kini (CFO); KKR fully exited 2021. (Fact.)

APPENDIX B — Source Appendix — Ingersoll Rand Inc. (NYSE: IR)

Report date 2026-06-26. Primary sources first. All SEC filings via EDGAR, CIK 0001699150. Third-party aggregated market/financial data is reconciled to filings; the filing governs where they disagree.

Primary — SEC Filings (EDGAR, CIK 0001699150)

Primary — Management Commentary (treated as hypothesis, validated against filings)

Secondary — Aggregated Quantitative Data (reconciled to filings)

Secondary — Industry & Competitive

Note: peer companies (Ametek, Roper, Emerson, Parker Hannifin, Chart Industries, Dover, IDEX, Graco, Atlas Copco) are referenced only for cohort/valuation comparison and do not imply any position in IR or in the peers.